RenovoRx IncChange company Symbol lookupSelect an option...RNXT RenovoRx IncPPG PPG Industries IncKBNT Kubient IncHOSZY Haci Omer Sabanci Holding ASFREJN Federal Home Loan Mortgage CorpNXPL NextPlat Corp$QCF E-MINI NASDAQ COMPOSITE SPOT FIXCURI CuriosityStream IncAXDX Accelerate Diagnostics IncMS-I Morgan StanleyGo
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in delivering its targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. The Company’s therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) utilizes chemotherapeutics. RenovoTAMP combines its patented delivery system, RenovoCath, with small molecule chemotherapeutic agents, which can be forced across the vessel wall using pressure, targeting these anti-cancer drugs locally to the solid tumors. Its first product candidate, RenovoGem, is a drug /device combination consisting of intra-arterial gemcitabine and RenovoCath. RenovoGem has been developed for the treatment of two rare diseases: pancreatic cancer and cholangiocarcinoma (CCA). It has completed the first of two planned interim analyses of the ongoing open-label Phase III TIGeR-PaC clinical trial.
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| May 12, 2023 | Q1 2023 Earnings Release | -$0.36 | -$0.25 to -$0.25 | -$0.33 |
| March 2, 2023 | Q4 2022 Earnings Release | -$0.23 | -$0.26 to -$0.26 | -$0.12 |
| November 14, 2022 | Q3 2022 Earnings Release | -$0.24 | -$0.31 to -$0.27 | -$0.27 |
| August 12, 2022 | Q2 2022 Earnings Release | -$0.29 | -$0.31 to -$0.26 | -- |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.